Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. - Wikidata - wikimedia - TriplyDB

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

http://www.wikidata.org/entity/Q35034575

about

Gene expression analysis in RA: towards personalized medicine Genomic profiling in luminal breast cancer Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Biological subtypes of breast cancer: Prognostic and therapeutic implications.Genome-based risk prediction for early stage breast cancer.Markers for the identification of late breast cancer recurrence.Nomogram for predicting breast conservation after neoadjuvant chemotherapy.PROGgeneV2: enhancements on the existing database Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer.Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study Gene signatures in breast cancer: current and future uses.Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer Identification and prioritization of candidate genes for symptom variability in breast cancer survivors based on disease characteristics at the cellular level.HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.Practical implications of gene-expression-based assays for breast oncologists.From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.Breast Cancer Biomarkers: Utility in Clinical Practice.Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors.Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.Integrating breast cancer genetics into clinical practice.Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.Indications for prognostic gene expression profiling in early breast cancer.Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer.Clinical utility of gene-expression signatures in early stage breast cancer.Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database study.An unmet need: tailoring extended adjuvant endocrine therapy.Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.

P2860

Q26825706-19ACD04F-F6E8-45E2-B529-21C9AA0C1D42 Q26862681-0B13C768-4C3A-4BCA-BBD8-681F22AD698F Q27020973-6D447A49-93CB-4F1D-AD02-86DF6694D256 Q28077637-D67C847D-E506-4BC9-B06A-C82FA9B71AFF Q28079118-B1F38914-C2F2-4423-B908-1ABD8C6929FB Q33834198-2E19CECF-7892-4A1C-89A4-0276870921E9 Q34023695-8FAE4D72-0BFE-4793-9076-31127332E093 Q34359289-B3A398C2-4A73-4E73-940F-67D2136D02A0 Q35018949-FC348F69-15A4-45DC-899D-A8ED6095056C Q35429810-8CC62708-C11C-4C9F-9BCF-BEA39BE5EC31 Q35527541-00FB5FB8-048A-4CC5-9E50-F9B11DFBF8D8 Q35683583-B738BEB8-F6A4-441C-8162-E7164416805D Q36245350-AE14594E-B7F8-4BD0-8ACB-6CE63C394726 Q36428743-C76327C7-AAAB-4A95-A71F-518FB7BCE577 Q36525765-5504D5A3-E4FA-474A-98EE-5408513656F9 Q36547919-CF33B25E-1318-4623-A927-C6517293F5F8 Q36684067-285176BE-0C76-4562-9DEF-68FBC3E0189F Q36903062-DAC9E432-5ED5-4FDE-A4D2-405A80364013 Q36989546-9A9ED939-B5E4-4D2D-A2A8-02358BEAD072 Q37214217-DAEE096A-31AE-41D0-9F98-261439C2CBE4 Q37441159-26534D35-2787-42F5-965F-E8F2BB903BAD Q37570901-BCD00F3E-A898-423E-94EB-FB4FE86864AB Q37591446-C3B63C50-3706-4229-A4E0-E6B572D99847 Q37668201-7D72DF48-1BB5-4E10-9E63-2857E3951937 Q37690538-85BD66DD-4DEC-4AB3-8A31-A2E647509DB7 Q37691657-36EFD0D5-B749-49AA-B3F0-C21B020069C2 Q37723758-064558EE-40A3-4E16-81AD-BE4065E3934F Q37968654-381D6D38-BFE0-4353-9AD4-979D73A97179 Q37992403-4F77D1F1-548A-49BB-A6E1-F5424088ED99 Q38236904-07CBEC97-6BB4-46A0-BD19-4EB2CC7E96DB Q38451798-A0F77E4E-B0C4-4CB6-84F6-BE032D08E42B Q38635960-38DFBEB0-DCF8-4BFB-864E-7C2C681791E1 Q38754717-5ABFD5D7-B483-4A8D-905E-890B186AA338 Q42353297-FA2A9CA9-EC4B-4CD8-946D-3640545FE0CA Q42670058-94040CD2-BA2A-43DE-9CC9-54478A8012C3 Q42813847-A9B582D0-F9F9-47EE-8487-DA56EBB4ABE0 Q44296908-D62515E8-2D63-47E9-A5A1-78DBAFECCF9C Q45982151-316CFFF8-B33C-4DC8-B1B8-F4057BCB106A Q49951544-797B8C8F-2DD0-489B-9325-0E3C40F6D6C0 Q51772667-4C66E702-A97C-4DB8-9F73-6DE123BBB136

P2860

Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial.

http://www.wikidata.org/entity/Q35034575

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Prognostic utility of HOXB13:I ...... ents from the Stockholm trial.

@ast

Prognostic utility of HOXB13:I ...... ents from the Stockholm trial.

@en

type

label

Prognostic utility of HOXB13:I ...... ents from the Stockholm trial.

@ast

Prognostic utility of HOXB13:I ...... ents from the Stockholm trial.

@en

prefLabel

Prognostic utility of HOXB13:I ...... ents from the Stockholm trial.

@ast

Prognostic utility of HOXB13:I ...... ents from the Stockholm trial.

@en

P1433

Q35034575-F2E7D618-53FC-43A3-9515-9C0258FDE523

P1476

Q35034575-27EE0D00-C3BC-423E-81FC-6E284C18CC43

P2093

Q35034575-1649B5DB-385C-4CB8-A647-F293D1087734

Q35034575-20E49627-863B-4B9E-9E0A-38B91615091A

Q35034575-212C808D-AFBD-42CA-ACAC-7D9851B6257D

Q35034575-3C90EB87-E81C-4ADB-9C09-03515E9A6642

Q35034575-45D493F4-68B0-4EF0-B144-D8D582C71533

Q35034575-6993C9C7-F443-4646-A4E0-FF4D04685E31

Q35034575-AAC3C6D9-7C38-4C2C-B979-01B5C65E9DBA

Q35034575-ABED63AF-E97B-44CD-8B86-0063360FFD34

Q35034575-BDB255B6-5289-41F5-99C0-AD0F47071E75

Q35034575-CF26EADB-2DB1-44E0-BDA6-8F748DE3CE9A

P2860

Q35034575-18EFA30E-9AC7-4C66-AC19-008CF1105E68

Q35034575-2793DBFA-283D-48AD-8EC2-2F7714D4295D

Q35034575-444DF6F5-48CB-474F-9374-2C0AB1CED89E

Q35034575-471EC930-9F81-4FA3-8AFB-02A9A95C9043

Q35034575-533AF93E-1E2C-4222-909A-F91C02959AF3

Q35034575-5C4E2283-12C6-44AA-9624-2AD845FB54FC

Q35034575-672FCE06-6C51-4145-B063-7A8E680300B7

Q35034575-6D9489EE-F5EE-40DC-A267-993713FD3AA6

Q35034575-6E11076B-16F8-477C-85D1-7FE6F3BD9B90

Q35034575-7E32B28A-97D4-40AB-9536-BE7236FDEF20

P2888

Q35034575-38F63CB4-87B0-4418-BA8D-787A39CF4EBE

P304

Q35034575-5EE1CBE3-BA37-4673-A74F-038BF086EF0C

P31

Q35034575-2E6943C7-3342-4770-BBBB-D82BB2DE8085

P356

Q35034575-12A0FBA0-FF68-4D61-8FFB-1EAC6225D95E

P407

Q35034575-1C345199-9CB9-4FC1-87FD-0D94796E4746

P433

Q35034575-710947F3-A703-48DC-8DCA-831645A7B54F

P478

Q35034575-DC2CAE4F-FDB6-4D4C-A11D-A5DE7D406B49

P577

Q35034575-67AA25CB-28EA-4412-AC23-1BC3114A085D

P5875

Q35034575-675F5D86-9A2E-48EE-9DCF-FCB23E6CBBE1

P6179

Q35034575-42D8A88B-1C90-417B-8EEE-01B9D58597A4

P698

Q35034575-E0BA46A6-A6FA-40AA-A601-5981DE4C53EC

P932

Q35034575-47448FD3-4972-4BB8-8653-13521F5304C9

P356

P1433

British Journal of Cancer

P1476

Prognostic utility of HOXB13:I ...... ents from the Stockholm trial.

@en

P2093

B Holmlund

http://www.w3.org/2001/XMLSchema#string

B Nordenskjöld

http://www.w3.org/2001/XMLSchema#string

D C Sgroi

http://www.w3.org/2001/XMLSchema#string

H Li

http://www.w3.org/2001/XMLSchema#string

L Skoog

http://www.w3.org/2001/XMLSchema#string

M G Erlander

http://www.w3.org/2001/XMLSchema#string

N C Kesty

http://www.w3.org/2001/XMLSchema#string

O Stål

http://www.w3.org/2001/XMLSchema#string

P-L Jerevall

http://www.w3.org/2001/XMLSchema#string

R Salunga

http://www.w3.org/2001/XMLSchema#string

P2860

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

A gene-expression signature as a predictor of survival in breast cancer

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer

Concordance among gene-expression-based predictors for breast cancer.

Proliferation: the most prominent predictor of clinical outcome in breast cancer.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

P2888

P304

1762-1769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.145

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51114089

http://www.w3.org/2001/XMLSchema#string

P6179

1013332982

http://www.w3.org/2001/XMLSchema#string

P698

21559019

http://www.w3.org/2001/XMLSchema#string

P932

3111159

http://www.w3.org/2001/XMLSchema#string